BM-MSC Accelerates Acute Stroke Recovery

BM-MSC Accelerates Acute Stroke Recovery In a Randomized Placebo-controlled Clinical Phase II/III Study

MI Norlinah1 , HJ Tan1 , SP Chin3 , ZK Law1 , I Nor Azimah2 , NA Nur’Ain3 , SK Cheong3,4, SAW Fadilah1,2 

1 Department of Medicine, 2 Cell Therapy Center, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 3 Cytopeutics, Malaysia, 4 Tunku Abdul Rahman University, Malaysia. 

Our results showed that patients with acute stroke who received BM-MSC infusion benefited from significant improvement in clinical disability and functional outcome as early as 6 weeks of follow-up. The benefit was sustained up to 12 months follow-up and may potentially reduce mortality from sepsis.

NIHSS

Figure 1: The mean of NIHSS score at baseline and after (6 weeks, 3, 6, 9 and 12 months) BM-MSC infusion. *One-way ANOVA. Scheffe’s post-hoc multiple comparison was used to test the difference between each visit (p<0.05).

barthel index

Figure 2: The mean of Barthel Index score at baseline and after (6 weeks, 3, 6, 9 and 12 months) BM-MSC infusion. *One-way ANOVA Scheffe’s post-hoc multiple comparison was used to test the difference between each visit (p=0.04).